Oncobiologics, Inc. and inVentiv Health have entered a strategic partnership for the clinical development of Oncobiologic’s pipeline. The global partnership will initially focus on biosimilar assets, including generic versions of Humira, Rituxan, Avastin, Herceptin and Erbitux, and could be expanded to include innovative molecules. inVentiv will lead and execute clinical studies, provide bioanalytical support for trials, and may also contribute commercialization capabilities in select coun...